Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma

Authors: Jing-Yan Cao, Li Liu, Shu-Peng Chen, Xing Zhang, Yan-Jun Mi, Zhi-Gang Liu, Man-Zhi Li, Hua Zhang, Chao-Nan Qian, Jian-Yong Shao, Li-Wu Fu, Yun-Fei Xia, Mu-Sheng Zeng

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Our recent cDNA microarray data showed that centromere protein F (CENP-F) is significantly upregulated in primary cultured nasopharyngeal carcinoma (NPC) tumor cells compared with normal nasopharyngeal epithelial cells. The goal of this study was to further investigate the levels of CENP-F expression in NPC cell lines and tissues to clarify the clinical significance of CENP-F expression in NPC as well as the potential therapeutic implications of CENP-F expression.

Methods

Real-time RT-PCR and western blotting were used to examine CENP-F expression levels in normal primary nasopharyngeal epithelial cells (NPEC), immortalized nasopharyngeal epithelial cells and NPC cell lines. Levels of CENP-F mRNA were determined by real-time RT-PCR in 23 freshly frozen nasopharyngeal biopsy tissues, and CENP-F protein levels were detected by immunohistochemistry in paraffin sections of 202 archival NPC tissues. Statistical analyses were applied to test for prognostic associations. The cytotoxicities of CENP-F potential target chemicals, zoledronic acid (ZOL) and FTI-277 alone, or in combination with cisplatin, in NPC cells were determined by the MTT assay.

Results

The levels of CENP-F mRNA and protein were higher in NPC cell lines than in normal and immortalized NPECs. CENP-F mRNA level was upregulated in nasopharyngeal carcinoma biopsy tissues compared with noncancerous tissues. By immunohistochemical analysis, CENP-F was highly expressed in 98 (48.5%) of 202 NPC tissues. Statistical analysis showed that high expression of CENP-F was positively correlated with T classification (P < 0.001), clinical stage (P < 0.001), skull-base invasion (P < 0.001) and distant metastasis (P = 0.012) inversely correlated with the overall survival time in NPC patients. Multivariate analysis showed that CENP-F expression was an independent prognostic indicator for the survival of the patient. Moreover, we found that ZOL or FTI-277 could significantly enhance the chemotherapeutic sensitivity of NPC cell lines (HONE1 and 6-10B) with high CENP-F expression to cisplatin, although ZOL or FTI-277 alone only exhibited a minor inhibitory effect to NPC cells.

Conclusion

Our data suggest that CENP-F protein is a valuable marker of NPC progression, and CENP-F expression is associated with poor overall survival of patients. In addition, our data indicate a potential benefit of combining ZOL or FTI-277 with cisplatin in NPC suggesting that CENP-F expression may have therapeutic implications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL: Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006, 6: 178- 10.1186/1471-2407-6-178PubMedCentralCrossRefPubMed Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL: Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006, 6: 178- 10.1186/1471-2407-6-178PubMedCentralCrossRefPubMed
2.
go back to reference Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-247. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-ZCrossRefPubMed Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-247. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-ZCrossRefPubMed
3.
go back to reference Lo KW, Huang DP: Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002, 12: 451-462. 10.1016/S1044579X02000883CrossRefPubMed Lo KW, Huang DP: Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002, 12: 451-462. 10.1016/S1044579X02000883CrossRefPubMed
4.
go back to reference Yamashita S, Kondo M, Hashimoto S: Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy. Acta Radiol Oncol. 1985, 24: 315-320. 10.3109/02841868509136058CrossRefPubMed Yamashita S, Kondo M, Hashimoto S: Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy. Acta Radiol Oncol. 1985, 24: 315-320. 10.3109/02841868509136058CrossRefPubMed
5.
go back to reference Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH: Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope. 1992, 102: 965-972.PubMed Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH: Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope. 1992, 102: 965-972.PubMed
6.
go back to reference Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E: Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994, 21: 382-397.PubMed Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E: Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994, 21: 382-397.PubMed
7.
go back to reference Bomont P, Maddox P, Shah JV, Desai AB, Cleveland DW: Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. Embo J. 2005, 24: 3927-3939. 10.1038/sj.emboj.7600848PubMedCentralCrossRefPubMed Bomont P, Maddox P, Shah JV, Desai AB, Cleveland DW: Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. Embo J. 2005, 24: 3927-3939. 10.1038/sj.emboj.7600848PubMedCentralCrossRefPubMed
8.
go back to reference Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS: Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci. 2005, 118: 4889-4900. 10.1242/jcs.02614CrossRefPubMed Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS: Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci. 2005, 118: 4889-4900. 10.1242/jcs.02614CrossRefPubMed
9.
go back to reference Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ: CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995, 130: 507-518. 10.1083/jcb.130.3.507CrossRefPubMed Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ: CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995, 130: 507-518. 10.1083/jcb.130.3.507CrossRefPubMed
10.
go back to reference Hussein D, Taylor SS: Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002, 115: 3403-3414.PubMed Hussein D, Taylor SS: Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002, 115: 3403-3414.PubMed
11.
go back to reference Varis A, Salmela AL, Kallio MJ: Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006, 115: 288-295. 10.1007/s00412-005-0046-0CrossRefPubMed Varis A, Salmela AL, Kallio MJ: Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006, 115: 288-295. 10.1007/s00412-005-0046-0CrossRefPubMed
12.
go back to reference Ma L, Zhao X, Zhu X: Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci. 2006, 13: 205-213. 10.1007/s11373-005-9057-3CrossRefPubMed Ma L, Zhao X, Zhu X: Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci. 2006, 13: 205-213. 10.1007/s11373-005-9057-3CrossRefPubMed
13.
go back to reference Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI: Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther. 2007, 6: 1317-1328. 10.1158/1535-7163.MCT-06-0703CrossRefPubMed Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI: Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther. 2007, 6: 1317-1328. 10.1158/1535-7163.MCT-06-0703CrossRefPubMed
14.
go back to reference Brown HK, Ottewell PD, Coleman RE, Holen I: The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2009 Brown HK, Ottewell PD, Coleman RE, Holen I: The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2009
15.
go back to reference Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler MJ: High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med. 1997, 20: 308-319.PubMed Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler MJ: High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med. 1997, 20: 308-319.PubMed
16.
go back to reference Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G: Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol. 1999, 12: 69-74.PubMed Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G: Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol. 1999, 12: 69-74.PubMed
17.
go back to reference Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol. 2005, 41: 716-722. 10.1016/j.oraloncology.2005.03.008CrossRefPubMed Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol. 2005, 41: 716-722. 10.1016/j.oraloncology.2005.03.008CrossRefPubMed
18.
go back to reference Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R: Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol. 2005, 18: 1223-1231. 10.1038/modpathol.3800409CrossRefPubMed Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R: Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol. 2005, 18: 1223-1231. 10.1038/modpathol.3800409CrossRefPubMed
19.
go back to reference Konstantinidou AE, Korkolopoulou P, Kavantzas N, Mahera H, Thymara I, Kotsiakis X, Perdiki M, Patsouris E, Davaris P: Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol Histopathol. 2003, 18: 67-74.PubMed Konstantinidou AE, Korkolopoulou P, Kavantzas N, Mahera H, Thymara I, Kotsiakis X, Perdiki M, Patsouris E, Davaris P: Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol Histopathol. 2003, 18: 67-74.PubMed
20.
go back to reference O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007, 120: 1434-1443. 10.1002/ijc.22413CrossRefPubMed O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer. 2007, 120: 1434-1443. 10.1002/ijc.22413CrossRefPubMed
21.
go back to reference Shao JY, Zeng WF, Zeng YX: [Molecular genetic progression on nasopharyngeal carcinoma]. Ai Zheng. 2002, 21: 1-10.PubMed Shao JY, Zeng WF, Zeng YX: [Molecular genetic progression on nasopharyngeal carcinoma]. Ai Zheng. 2002, 21: 1-10.PubMed
22.
go back to reference Li RP, Shao JY, Deng L, Zeng MS, Song LB, Li MZ, Wu QL: [Identification of differentially expressed genes in primary cultured nasopharyngeal carcinoma cells by cDNA microarray]. Nan Fang Yi Ke Da Xue Xue Bao. 2007, 27: 1156-1160.PubMed Li RP, Shao JY, Deng L, Zeng MS, Song LB, Li MZ, Wu QL: [Identification of differentially expressed genes in primary cultured nasopharyngeal carcinoma cells by cDNA microarray]. Nan Fang Yi Ke Da Xue Xue Bao. 2007, 27: 1156-1160.PubMed
23.
go back to reference Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008, 20: 264-269. 10.1097/CCO.0b013e3282fad846CrossRefPubMed Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008, 20: 264-269. 10.1097/CCO.0b013e3282fad846CrossRefPubMed
24.
go back to reference Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002, 42: 1228-1236. 10.1177/009127002762491316CrossRefPubMed Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002, 42: 1228-1236. 10.1177/009127002762491316CrossRefPubMed
25.
go back to reference Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004, 53: 235-240. 10.1136/gut.2003.021238PubMedCentralCrossRefPubMed Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004, 53: 235-240. 10.1136/gut.2003.021238PubMedCentralCrossRefPubMed
26.
go back to reference de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A: CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck. 2001, 23: 104-112. 10.1002/1097-0347(200102)23:2<104::AID-HED1005>3.0.CO;2-0CrossRefPubMed de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A: CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck. 2001, 23: 104-112. 10.1002/1097-0347(200102)23:2<104::AID-HED1005>3.0.CO;2-0CrossRefPubMed
27.
go back to reference Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006, 38: 1043-1048. 10.1038/ng1861CrossRefPubMed Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006, 38: 1043-1048. 10.1038/ng1861CrossRefPubMed
28.
go back to reference Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick UJ, Pawitan Y, Alaiya A, Sennerstam R, Zetterberg A, Auer G: Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res. 2004, 64: 904-909. 10.1158/0008-5472.CAN-03-2451CrossRefPubMed Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick UJ, Pawitan Y, Alaiya A, Sennerstam R, Zetterberg A, Auer G: Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res. 2004, 64: 904-909. 10.1158/0008-5472.CAN-03-2451CrossRefPubMed
29.
go back to reference Schvartzman JM, Sotillo R, Benezra R: Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 2010, 10: 102-115. 10.1038/nrc2781CrossRefPubMed Schvartzman JM, Sotillo R, Benezra R: Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 2010, 10: 102-115. 10.1038/nrc2781CrossRefPubMed
30.
go back to reference Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y, Tsao SW: Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis. 2000, 21: 2293-2297. 10.1093/carcin/21.12.2293CrossRefPubMed Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y, Tsao SW: Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis. 2000, 21: 2293-2297. 10.1093/carcin/21.12.2293CrossRefPubMed
31.
go back to reference Mao Y, Desai A, Cleveland DW: Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol. 2005, 170: 873-880. 10.1083/jcb.200505040PubMedCentralCrossRefPubMed Mao Y, Desai A, Cleveland DW: Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol. 2005, 170: 873-880. 10.1083/jcb.200505040PubMedCentralCrossRefPubMed
32.
go back to reference Schaar BT, Chan GK, Maddox P, Salmon ED, Yen TJ: CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol. 1997, 139: 1373-1382. 10.1083/jcb.139.6.1373PubMedCentralCrossRefPubMed Schaar BT, Chan GK, Maddox P, Salmon ED, Yen TJ: CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol. 1997, 139: 1373-1382. 10.1083/jcb.139.6.1373PubMedCentralCrossRefPubMed
33.
go back to reference Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW: Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell. 2002, 3: 351-365. 10.1016/S1534-5807(02)00255-1CrossRefPubMed Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW: Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell. 2002, 3: 351-365. 10.1016/S1534-5807(02)00255-1CrossRefPubMed
34.
go back to reference Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, Yoda K, Nomura F: Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res. 2005, 65: 4683-4689. 10.1158/0008-5472.CAN-04-3613CrossRefPubMed Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, Yoda K, Nomura F: Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res. 2005, 65: 4683-4689. 10.1158/0008-5472.CAN-04-3613CrossRefPubMed
35.
go back to reference Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007, 13: 508-514. 10.1158/1078-0432.CCR-06-1512CrossRefPubMed Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007, 13: 508-514. 10.1158/1078-0432.CCR-06-1512CrossRefPubMed
36.
go back to reference Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005, 65: 4971-4974. 10.1158/0008-5472.CAN-05-0264CrossRefPubMed Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005, 65: 4971-4974. 10.1158/0008-5472.CAN-05-0264CrossRefPubMed
37.
go back to reference Green JR: Bisphosphonates: preclinical review. Oncologist. 2004, 9 (Suppl 4): 3-13. 10.1634/theoncologist.9-90004-3CrossRefPubMed Green JR: Bisphosphonates: preclinical review. Oncologist. 2004, 9 (Suppl 4): 3-13. 10.1634/theoncologist.9-90004-3CrossRefPubMed
38.
go back to reference Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR: Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA. 107: 5839-5844. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR: Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA. 107: 5839-5844.
39.
go back to reference Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094CrossRefPubMed Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094CrossRefPubMed
40.
go back to reference Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10: 8465-8471. 10.1158/1078-0432.CCR-04-0653CrossRefPubMed Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10: 8465-8471. 10.1158/1078-0432.CCR-04-0653CrossRefPubMed
41.
go back to reference Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6: 4064-4068.PubMed Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6: 4064-4068.PubMed
42.
go back to reference Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2006, 5: 39-47.CrossRefPubMed Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2006, 5: 39-47.CrossRefPubMed
43.
go back to reference Jin ZJ: About the evaluation of drug combination. Acta Pharmacol Sin. 2004, 25: 146-147.PubMed Jin ZJ: About the evaluation of drug combination. Acta Pharmacol Sin. 2004, 25: 146-147.PubMed
Metadata
Title
Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma
Authors
Jing-Yan Cao
Li Liu
Shu-Peng Chen
Xing Zhang
Yan-Jun Mi
Zhi-Gang Liu
Man-Zhi Li
Hua Zhang
Chao-Nan Qian
Jian-Yong Shao
Li-Wu Fu
Yun-Fei Xia
Mu-Sheng Zeng
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-237

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine